2-(Piperazin-1-yl)-N-(p-tolyl)acetamide

Catalog No.: 
ACIOTP350
CAS No.: 
89473-82-5
Molecular Formula: 
C13H19N3O
Molecular Weight: 
233.32
2-(Piperazin-1-yl)-N-(p-tolyl)acetamide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg96%$311.00InquiryInquiry
1g96%$745.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2-(Piperazin-1-yl)-N-(p-tolyl)acetamide
IUPAC Name2-(piperazin-1-yl)-N-(p-tolyl)acetamide
MDL No.MFCD06386688
Molecular FormulaC13H19N3O
Molecular Weight233.32
SMILESO=C(NC1=CC=C(C)C=C1)CN2CCNCC2
InChI KeyMDAZMMIENIDQQN-UHFFFAOYSA-N
SynonymN-(4-METHYLPHENYL)-2-PIPERAZIN-1-YLACETAMIDE;AKOS BBS-00006342;N-(4-methylphenyl)-2-(1-piperazinyl)acetamide;N-(4-methylphenyl)-2-piperazin-1-yl-ethanamide;2-Piperazin-1-yl-N-p-tolyl-acetamide;1-Piperazineacetamide, n-(4-methylphenyl)-, dihydrochloride;1-Piperazineacetamide, N-(4-methylphenyl)-
CAS No.89473-82-5

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACIOTP350 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACIOTP350 route product structure diagram
    ACIOTP35089473-82-5
Inquiry

2. ACIOTP350 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACIOTP350 route product structure diagram
    ACIOTP35089473-82-5
Inquiry

3. ACIOTP350 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACIOTP350 route product structure diagram
    ACIOTP35089473-82-5
Inquiry

Comments (0)